Assessment of cardiomyocyte contraction in human-induced pluripotent stem cell-derived cardiomyocytes

Toxicological Sciences

Volumn 144, Issue 2, 2015, Pages 227-237

  Pointon, Amy ^a   Harmer, Alexander R ^a   Dale, Ian L ^a   Abi Gerges, Najah ^a   Bowes, Joanne ^a   Pollard, Christopher ^a   Garside, Helen ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Cardiotoxicity; Drug discovery and development; hiPS CMs

Indexed keywords

CALCIUM;

ARTICLE; CALCIUM CELL LEVEL; CARDIOTOXICITY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG DEVELOPMENT; HEART CONTRACTION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INOTROPISM; MEASUREMENT; MUSCLE FIBER CONTRACTION; PLURIPOTENT STEM CELL; SAFETY; SENSITIVITY AND SPECIFICITY; CELL DIFFERENTIATION; CYTOLOGY; METABOLISM;

CALCIUM; CELL DIFFERENTIATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC;

EID: 84926466740     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu312     Document Type: Article

References (46)

1. Abassi, Y. A., Xi, B., Li, N., Ouyang, W., Seiler, A., Watzele, M., Kettenhofen, R., Bohlen, H., Ehlich, A., Kolossov, E., et al. (2012). Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br. J. Pharmacol. 165, 1424-1441.
2. Abi-Gerges, N., Pointon, A., Pullen, G. F., Morton, M. J., Oldman, K. L., Armstrong, D., Valentin, J. P., and Pollard, C. E. (2013). Preservation of cardiomyocytes from the adult heart. J. Mol. Cell. Cardiol. 64, 108-119.
3. Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., and Noonan, D. M. (2010). Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J. Natl. Cancer Inst. 102, 14-25.
4. Bokenes, J., Sjaastad, I., and Sejersted, O. M. (2005). Artifactual contractions triggered by field stimulation of cardiomyocytes. J. Appl. Physiol. (1985) 98, 1712-1719.
5. Caspi, O., Itzhaki, I., Kehat, I., Gepstein, A., Arbel, G., Huber, I., Satin, J., and Gepstein, L. (2009). In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev. 18, 161-172.
6. Cerignoli, F., Charlot, D., Whittaker, R., Ingermanson, R., Gehalot, P., Savchenko, A., Gallacher, D. J., Towart, R., Price, J. H., McDonough, P. M., et al. (2012). High throughput measurement of Ca(2)({thorn}) dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry. J. Pharmacol. Toxicol. Methods 66, 246-256.
7. Clements, M., and Thomas, N. (2014). High-throughput multiparameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays. Toxicol. Sci. 140, 445-461.
8. Cohen, L., Vereault, D., Wasserstrom, J. A., Retzinger, G. S., and Kezdy, F. J. (1987). Evidence that uncharged verapamil inhibits myocardial contractility. J. Pharmacol. Exp. Ther. 242, 721-725.
9. Force, T., Krause, D. S., and Van Etten, R. A. (2007). Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7, 332-344.
10. Genschow, E., Spielmann, H., Scholz, G., Seiler, A., Brown, N., Piersma, A., Brady, M., Clemann, N., Huuskonen, H., Paillard, F., et al.(2002). The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods. Altern. Lab. Anim. 30, 151-176.
11. Grosberg, A., Alford, P. W., McCain, M. L., and Parker, K. K. (2011). Ensembles of engineered cardiac tissues for physiological and pharmacological study: heart on a chip. Lab Chip 11, 4165-4173.
12. Grosberg, A., Nesmith, A. P., Goss, J. A., Brigham, M. D., McCain, M. L., and Parker, K. K. (2012). Muscle on a chip: in vitro contractility assays for smooth and striated muscle. J. Pharmacol. Toxicol. Methods 65, 126-135.
13. Guo, L., Abrams, R., Babiarz, J. E., Cohen, J. D., Kameoka, S., Sanders, M. J., Chiao, E., and Kolaja, K. L. (2011). Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell derived cardiomyocytes. Toxicol. Sci. 123, 281-289.
14. Guo, L., Dong, Z., and Guthrie, H. (2009). Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates. J. Pharmacol. Toxicol. Methods 60, 130-151.
15. Gwathmey, J. K., Tsaioun, K., and Hajjar, R. J. (2009). Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates. Expert Opin. Drug Metab. Toxicol. 5, 647-660.
16. Harmer, A. R., Abi-Gerges, N., Morton, M. J., Pullen, G. F., Valentin, J. P., and Pollard, C. E. (2012). Validation of an in vitro contractility assay using canine ventricular myocytes. Toxicol. Appl. Pharmacol. 260, 162-172.
17. Harris, K., Aylott, M., Cui, Y., Louttit, J. B., McMahon, N. C., and Sridhar, A. (2013). Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol. Sci. 134, 412-426.
18. Hoekstra, M., Mummery, C. L., Wilde, A. A., Bezzina, C. R., and Verkerk, A. O. (2012). Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias. Front. Physiol. 3, 346.
19. Hu, N., Wang, T., Wang, Q., Zhou, J., Zou, L., Su, K., Wu, J., and Wang, P. (2014). High-performance beating pattern function of human induced pluripotent stem cell-derived cardiomyocyte-based biosensors for hERG inhibition recognition. Biosens. Bioelectron. ahead of print.
20. Hussain, M., and Orchard, C. H. (1997). Sarcoplasmic reticulum Ca2{thorn} content, L-type Ca2{thorn} current and the Ca2{thorn} transient in rat myocytes during beta-adrenergic stimulation. J. Physiol. 505(Pt 2), 385-402.
21. Jonsson, M. K., Wang, Q. D., and Becker, B. (2011). Impedancebased detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes. Assay Drug Dev. Technol. 9, 589-599.
22. Landmesser, U., and Drexler, H. (2007). Update on inotropic therapy in the management of acute heart failure. Curr. Treat. Options Cardiovasc. Med. 9, 443-449.
23. Lasko, T. A., Bhagwat, J. G., Zou, K. H., and Ohno-Machado, L. (2005). The use of receiver operating characteristic curves in biomedical informatics. J. Biomed. Inform. 38, 404-415.
24. Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., et al.(2011). How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br. J. Pharmacol. 163, 675-693.
25. Li, S., Chen, G., and Li, R. A. (2013). Calcium signalling of human pluripotent stem cell-derived cardiomyocytes. J. Physiol. 591, 5279-5290.
26. Lieu, D. K., Liu, J., Siu, C. W., McNerney, G. P., Tse, H. F., Abu-Khalil, A., Huser, T., and Li, R. A. (2009). Absence of transverse tubules contributes to non-uniform Ca(2{thorn}) wavefronts in mouse and human embryonic stem cell-derived cardiomyocytes. Stem Cells Dev. 18, 1493-1500.
27. Lin, Z., and Will, Y. (2012). Evaluation of drugs with specific organ toxicities in organ-specific cell lines. Toxicol. Sci. 126, 114-127.
28. Ma, J., Guo, L., Fiene, S. J., Anson, B. D., Thomson, J. A., Kamp, T. J., Kolaja, K. L., Swanson, B. J., and January, C. T. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301, H2006-H2017.
29. Matsuoka, S., Nawada, T., Hisatome, I., Miyamoto, J., Hasegawa, J., Kotake, H., and Mashiba, H. (1991). Comparison of Ca2{thorn} channel inhibitory effects of cibenzoline with verapamil on guinea-pig heart. Gen. Pharmacol. 22, 87-91.
30. Mellor, H. R., Bell, A. R., Valentin, J. P., and Roberts, R. R. (2011). Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci. 120, 14-32.
31. Mummery, C., Ward-van Oostwaard, D., Doevendans, P., Spijker, R., van den Brink, S., Hassink, R., van der Heyden, M., Opthof, T., Pera, M., de la Riviere, A. B., et al. (2003). Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 107, 2733-2740.
32. Murphy, C. A., and Dargie, H. J. (2007). Drug-induced cardiovascular disorders. Drug Saf. 30, 783-804.
33. Navarrete, E. G., Liang, P., Lan, F., Sanchez-Freire, V., Simmons, C., Gong, T., Sharma, A., Burridge, P. W., Patlolla, B., Lee, A. S., et al. (2013). Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 128, S3-S13.
34. Nguemo, F., Saric, T., Pfannkuche, K., Watzele, M., Reppel, M., and Hescheler, J. (2012). In vitro model for assessing arrhythmogenic properties of drugs based on highresolution impedance measurements. Cell. Physiol. Biochem. 29, 819-832.
35. Pointon, A., Abi-Gerges, N., Cross, M. J., and Sidaway, J. E. (2013). Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity. Toxicol. Sci. 132, 317-326.
36. Pollard, C. E., Valentin, J. P., and Hammond, T. G. (2008). Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br. J. Pharmacol. 154, 1538-1543.
37. Pollard, C. E., Abi Gerges, N., Bridgland-Taylor, M. H., Easter, A., Hammond, T. G., and Valentin, J. P. (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br. J. Pharmacol. 159, 12-21.
38. Qian, J., and Guo, L. (2010). Altered cytosolic Ca2{thorn} dynamics in cultured Guinea pig cardiomyocytes as an in vitro model to identify potential cardiotoxicants. Toxicol. in vitro 24, 960-972.
39. Schwinger, R. H., Bohm, M., and Erdmann, E. (1990). Negative inotropic properties of isradipine, nifedipine, diltiazem, and verapamil in diseased human myocardial tissue. J. Cardiovasc. Pharmacol. 15, 892-899.
40. Scott, C. W., Peters, M. F., and Dragan, Y. P. (2013). Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. Toxicol. Lett. 219, 49-58.
41. Scott, C. W., Zhang, X., Abi-Gerges, N., Lamore, S. D., Abassi, Y. A., and Peters, M. F. (2014). An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility. Toxicol. Sci. 142, 331-338.
42. Sirenko, O., Cromwell, E. F., Crittenden, C., Wignall, J. A., Wright, F. A., and Rusyn, I. (2013). Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity. Toxicol. Appl. Pharmacol. 273, 500-507.
43. Slordal, L., and Spigset, O. (2006). Heart failure induced by noncardiac drugs. Drug Saf. 29, 567-586.
44. Song, L. S., Guatimosim, S., Gomez-Viquez, L., Sobie, E. A., Ziman, A., Hartmann, H., and Lederer, W. J. (2005). Calcium biology of the transverse tubules in heart. Ann. N. Y. Acad. Sci. 1047, 99-111.
45. Spielmann, H., Seiler, A., Bremer, S., Hareng, L., Hartung, T., Ahr, H., Faustman, E., Haas, U., Moffat, G. J., Nau, H., et al. (2006). The practical application of three validated in vitro embryotoxicity tests. The report and recommendations of an ECVAM/ZEBET workshop (ECVAM workshop 57). Altern. Lab. Anim. 34, 527-538.
46. Xi, B., Wang, T., Li, N., Ouyang, W., Zhang, W., Wu, J., Xu, X., Wang, X., and Abassi, Y. A. (2011). Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System. J. Lab. Autom. 16, 415-421.